Descartes 30 / Cartesian Therapeutics - LARVOL DELTA

Study of Descartes-30 in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P1 | N=12 | Terminated | Sponsor: Cartesian Therapeutics | Phase classification: P1/2 ➔ P1 | N=30 ➔ 12 | Trial completion date: May 2024 ➔ Sep 2023 | Recruiting ➔ Terminated; Phase 1 enrollment completed. Further clinical development terminated

Enrollment change • Phase classification • Trial completion date • Trial termination • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Study of Descartes-30 in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Cartesian Therapeutics | Trial completion date: Sep 2022 ➔ May 2024 | Trial primary completion date: Sep 2022 ➔ May 2024

Trial completion date • Trial primary completion date • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Study of Descartes-30 in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P1/2; N=30; Recruiting; Sponsor: Cartesian Therapeutics; Trial primary completion date: Sep 2021 ➔ Sep 2022

Trial primary completion date • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases

Study of Descartes-30 in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P1/2; N=30; Recruiting; Sponsor: Cartesian Therapeutics; Not yet recruiting ➔ Recruiting

Enrollment open • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Cartesian Therapeutics Initiates Clinical Trial of First RNA-Engineered Cell Therapy for Acute Respiratory Distress Syndrome and COVID-19 (PRNewswire) - "Cartesian Therapeutics...today announced that it has initiated a Phase 1/2 clinical trial of its lead RNA-engineered mesenchymal stem cell (MSC) therapy, Descartes-30, in patients with moderate-to-severe acute respiratory distress syndrome....It is also the first cell therapy to specifically degrade NETs, webs of extracellular DNA and histones that entrap inflammatory cells, block alveoli and vessels, and drive the pathogenesis of ARDS and COVID-19."

Trial status • Infectious Disease • Novel Coronavirus Disease

Study of Descartes-30 in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P1/2; N=30; Not yet recruiting; Sponsor: Cartesian Therapeutics

New P1/2 trial • Acute Respiratory Distress Syndrome • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases